ID

30353

Description

https://clinicaltrials.gov/ct2/show/NCT00486954 Study ID: 104578 Clinical Study ID: EGF104578 Study Title: A Randomized, Multicenter, Open-label, Phase III Study of Lapatinib (GW572016) in Combination with weekly Paclitaxel versus weekly Paclitaxel alone in the second line treatment of ErbB2 amplified Advanced Gastric Cancer Patient Level Data: Clinicaltrials.gov Identifier: NCT00486954 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Product Sponsorship Transferred to Novartis Generic Name: lapatinib Trade Name: Tyverb,Tykerb,Tycerb Study Indication: Neoplasms, Gastrointestinal Tract CRF Seiten: 1288-1609

Lien

https://clinicaltrials.gov/ct2/show/NCT00486954

Mots-clés

Versions (1)
  1. 29/05/2018 29/05/2018 - Halim Ugurlu
Détendeur de droits

GlaxoSmithKline (GSK)

Téléchargé le

29 mai 2018

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 3.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

NCT00486954_Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer

Anglais

Safety Assessment of Interstitial Pneumonitis, Continutation, Status, Concominant Medications

1 Formulaires  
Safety Assessment of Interstitial Pneumonitis
Description

Safety Assessment of Interstitial Pneumonitis

Alias
UMLS CUI-1
C0206061
Was a chest CT, MRI or x-ray performed as surveillance for interstitial pneumonitis?
Description

If yes, record any findings in teh Adverse Events or Serious Adverse Events from as appropriate

Type de données

boolean

Alias
UMLS CUI [1,1]
C0206061
UMLS CUI [1,2]
C0920316
UMLS CUI [1,3]
C0733511
UMLS CUI [1,4]
C0011923
Continutation
Description

Continutation

Alias
UMLS CUI-1
C0805733
Will the subject start the next cycle?
Description

Continutation

Type de données

boolean

Alias
UMLS CUI [1]
C0805733
Status
Description

Status

Alias
UMLS CUI-1
C0449438
Were any concominant medications taken by the subject prior to screening and/or during study?
Description

concominant medication

Type de données

boolean

Alias
UMLS CUI [1]
C2347852
Did the subject experience any non-serious adverse events during the study?
Description

non-serious adverse events during the study

Type de données

boolean

Alias
UMLS CUI [1]
C1518404
Did the subject experience any serious adverse events during the study?
Description

Serious adverse events during the study

Type de données

boolean

Alias
UMLS CUI [1]
C1519255
Were any blood products or blood supportive care products used for the subject prior to screening and/or during study?
Description

Blood products or blood supportive care products use

Type de données

boolean

Alias
UMLS CUI [1,1]
C0456388
UMLS CUI [1,2]
C0457083
Concominant Medications
Description

Concominant Medications

Alias
UMLS CUI-1
C2347852
Drug name
Description

Trade name preferred

Type de données

text

Alias
UMLS CUI [1]
C2360065
Reason for medication
Description

Reason for medication

Type de données

text

Alias
UMLS CUI [1]
C2826696
Start Date
Description

Start Date

Type de données

date

Alias
UMLS CUI [1]
C0808070
Taken prior to study?
Description

Taken prior to study?

Type de données

boolean

Alias
UMLS CUI [1]
C2826667
Ongoing?
Description

Ongoing

Type de données

boolean

Alias
UMLS CUI [1]
C2826666
Retour au début de la page

Similar models

Safety Assessment of Interstitial Pneumonitis, Continutation, Status, Concominant Medications

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Safety Assessment of Interstitial Pneumonitis
C0206061 (UMLS CUI-1)
CT, MRI or x-ray performed as surveillance for interstitial pneumonitis
Item
Was a chest CT, MRI or x-ray performed as surveillance for interstitial pneumonitis?
boolean
C0206061 (UMLS CUI [1,1])
C0920316 (UMLS CUI [1,2])
C0733511 (UMLS CUI [1,3])
C0011923 (UMLS CUI [1,4])
Item Group
Continutation
C0805733 (UMLS CUI-1)
Continutation
Item
Will the subject start the next cycle?
boolean
C0805733 (UMLS CUI [1])
Item Group
Status
C0449438 (UMLS CUI-1)
concominant medication
Item
Were any concominant medications taken by the subject prior to screening and/or during study?
boolean
C2347852 (UMLS CUI [1])
non-serious adverse events during the study
Item
Did the subject experience any non-serious adverse events during the study?
boolean
C1518404 (UMLS CUI [1])
Serious adverse events during the study
Item
Did the subject experience any serious adverse events during the study?
boolean
C1519255 (UMLS CUI [1])
Blood products or blood supportive care products use
Item
Were any blood products or blood supportive care products used for the subject prior to screening and/or during study?
boolean
C0456388 (UMLS CUI [1,1])
C0457083 (UMLS CUI [1,2])
Item Group
Concominant Medications
C2347852 (UMLS CUI-1)
Drug name
Item
Drug name
text
C2360065 (UMLS CUI [1])
Reason for medication
Item
Reason for medication
text
C2826696 (UMLS CUI [1])
Start Date
Item
Start Date
date
C0808070 (UMLS CUI [1])
Taken prior to study?
Item
Taken prior to study?
boolean
C2826667 (UMLS CUI [1])
Ongoing
Item
Ongoing?
boolean
C2826666 (UMLS CUI [1])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial